Bitter tasting compounds dilate airways by inhibiting airway smooth muscle calcium oscillations and calcium sensitivity.
Identifieur interne : 000303 ( PubMed/Checkpoint ); précédent : 000302; suivant : 000304Bitter tasting compounds dilate airways by inhibiting airway smooth muscle calcium oscillations and calcium sensitivity.
Auteurs : Xiahui Tan [États-Unis] ; Michael J. SandersonSource :
- British journal of pharmacology [ 1476-5381 ] ; 2014.
Descripteurs français
- KwdFr :
- Animaux, Bronchodilatateurs (pharmacologie), Caféine (antagonistes et inhibiteurs), Caféine (pharmacologie), Chloroquine (pharmacologie), Composés d'ammonium quaternaire (pharmacologie), Femelle, Goût, Inhibiteurs de la phosphodiestérase (), Inhibiteurs de la phosphodiestérase (pharmacologie), Inhibiteurs des canaux calciques (), Inhibiteurs des canaux calciques (pharmacologie), Inositol 1,4,5-trisphosphate (analogues et dérivés), Inositol 1,4,5-trisphosphate (métabolisme), Muscles lisses (), Muscles lisses (cytologie), Muscles lisses (métabolisme), Poumon (), Poumon (cytologie), Poumon (métabolisme), Quinine (pharmacologie), Relâchement musculaire (), Ryanodine (antagonistes et inhibiteurs), Ryanodine (pharmacologie), Récepteurs couplés aux protéines G (agonistes), Récepteurs couplés aux protéines G (métabolisme), Récepteurs à l'inositol 1,4,5-triphosphate (agonistes), Récepteurs à l'inositol 1,4,5-triphosphate (métabolisme), Résistance aux substances (), Résistance des voies aériennes (), Signalisation du calcium (), Souris, Souris de lignée BALB C, Techniques in vitro.
- MESH :
- agonistes : Récepteurs couplés aux protéines G, Récepteurs à l'inositol 1,4,5-triphosphate.
- analogues et dérivés : Inositol 1,4,5-trisphosphate.
- antagonistes et inhibiteurs : Caféine, Ryanodine.
- cytologie : Muscles lisses, Poumon.
- métabolisme : Inositol 1,4,5-trisphosphate, Muscles lisses, Poumon, Récepteurs couplés aux protéines G, Récepteurs à l'inositol 1,4,5-triphosphate.
- pharmacologie : Bronchodilatateurs, Caféine, Chloroquine, Composés d'ammonium quaternaire, Inhibiteurs de la phosphodiestérase, Inhibiteurs des canaux calciques, Quinine, Ryanodine.
- Animaux, Femelle, Goût, Inhibiteurs de la phosphodiestérase, Inhibiteurs des canaux calciques, Muscles lisses, Poumon, Relâchement musculaire, Résistance aux substances, Résistance des voies aériennes, Signalisation du calcium, Souris, Souris de lignée BALB C, Techniques in vitro.
English descriptors
- KwdEn :
- Airway Resistance (drug effects), Animals, Bronchodilator Agents (pharmacology), Caffeine (antagonists & inhibitors), Caffeine (pharmacology), Calcium Channel Blockers (chemistry), Calcium Channel Blockers (pharmacology), Calcium Signaling (drug effects), Chloroquine (pharmacology), Drug Resistance (drug effects), Female, In Vitro Techniques, Inositol 1,4,5-Trisphosphate (analogs & derivatives), Inositol 1,4,5-Trisphosphate (metabolism), Inositol 1,4,5-Trisphosphate Receptors (agonists), Inositol 1,4,5-Trisphosphate Receptors (metabolism), Lung (cytology), Lung (drug effects), Lung (metabolism), Mice, Mice, Inbred BALB C, Muscle Relaxation (drug effects), Muscle, Smooth (cytology), Muscle, Smooth (drug effects), Muscle, Smooth (metabolism), Phosphodiesterase Inhibitors (chemistry), Phosphodiesterase Inhibitors (pharmacology), Quaternary Ammonium Compounds (pharmacology), Quinine (pharmacology), Receptors, G-Protein-Coupled (agonists), Receptors, G-Protein-Coupled (metabolism), Ryanodine (antagonists & inhibitors), Ryanodine (pharmacology), Taste.
- MESH :
- chemical , agonists : Inositol 1,4,5-Trisphosphate Receptors, Receptors, G-Protein-Coupled.
- chemical , analogs & derivatives : Inositol 1,4,5-Trisphosphate.
- chemical , antagonists & inhibitors : Caffeine, Ryanodine.
- chemical , chemistry : Calcium Channel Blockers, Phosphodiesterase Inhibitors.
- chemical , metabolism : Inositol 1,4,5-Trisphosphate, Inositol 1,4,5-Trisphosphate Receptors, Receptors, G-Protein-Coupled.
- chemical , pharmacology : Bronchodilator Agents, Caffeine, Calcium Channel Blockers, Chloroquine, Phosphodiesterase Inhibitors, Quaternary Ammonium Compounds, Quinine, Ryanodine.
- cytology : Lung, Muscle, Smooth.
- drug effects : Airway Resistance, Calcium Signaling, Drug Resistance, Lung, Muscle Relaxation, Muscle, Smooth.
- metabolism : Lung, Muscle, Smooth.
- Animals, Female, In Vitro Techniques, Mice, Mice, Inbred BALB C, Taste.
Abstract
While selective, bitter tasting, TAS2R agonists can relax agonist-contracted airway smooth muscle (ASM), their mechanism of action is unclear. However, ASM contraction is regulated by Ca²⁺ signalling and Ca²⁺ sensitivity. We have therefore investigated how the TAS2R10 agonists chloroquine, quinine and denotonium regulate contractile agonist-induced Ca²⁺ signalling and sensitivity.
DOI: 10.1111/bph.12460
PubMed: 24117140
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:24117140Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bitter tasting compounds dilate airways by inhibiting airway smooth muscle calcium oscillations and calcium sensitivity.</title>
<author><name sortKey="Tan, Xiahui" sort="Tan, Xiahui" uniqKey="Tan X" first="Xiahui" last="Tan">Xiahui Tan</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sanderson, Michael J" sort="Sanderson, Michael J" uniqKey="Sanderson M" first="Michael J" last="Sanderson">Michael J. Sanderson</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24117140</idno>
<idno type="pmid">24117140</idno>
<idno type="doi">10.1111/bph.12460</idno>
<idno type="wicri:Area/PubMed/Corpus">000323</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000323</idno>
<idno type="wicri:Area/PubMed/Curation">000323</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000323</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000303</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000303</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Bitter tasting compounds dilate airways by inhibiting airway smooth muscle calcium oscillations and calcium sensitivity.</title>
<author><name sortKey="Tan, Xiahui" sort="Tan, Xiahui" uniqKey="Tan X" first="Xiahui" last="Tan">Xiahui Tan</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sanderson, Michael J" sort="Sanderson, Michael J" uniqKey="Sanderson M" first="Michael J" last="Sanderson">Michael J. Sanderson</name>
</author>
</analytic>
<series><title level="j">British journal of pharmacology</title>
<idno type="eISSN">1476-5381</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Airway Resistance (drug effects)</term>
<term>Animals</term>
<term>Bronchodilator Agents (pharmacology)</term>
<term>Caffeine (antagonists & inhibitors)</term>
<term>Caffeine (pharmacology)</term>
<term>Calcium Channel Blockers (chemistry)</term>
<term>Calcium Channel Blockers (pharmacology)</term>
<term>Calcium Signaling (drug effects)</term>
<term>Chloroquine (pharmacology)</term>
<term>Drug Resistance (drug effects)</term>
<term>Female</term>
<term>In Vitro Techniques</term>
<term>Inositol 1,4,5-Trisphosphate (analogs & derivatives)</term>
<term>Inositol 1,4,5-Trisphosphate (metabolism)</term>
<term>Inositol 1,4,5-Trisphosphate Receptors (agonists)</term>
<term>Inositol 1,4,5-Trisphosphate Receptors (metabolism)</term>
<term>Lung (cytology)</term>
<term>Lung (drug effects)</term>
<term>Lung (metabolism)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Muscle Relaxation (drug effects)</term>
<term>Muscle, Smooth (cytology)</term>
<term>Muscle, Smooth (drug effects)</term>
<term>Muscle, Smooth (metabolism)</term>
<term>Phosphodiesterase Inhibitors (chemistry)</term>
<term>Phosphodiesterase Inhibitors (pharmacology)</term>
<term>Quaternary Ammonium Compounds (pharmacology)</term>
<term>Quinine (pharmacology)</term>
<term>Receptors, G-Protein-Coupled (agonists)</term>
<term>Receptors, G-Protein-Coupled (metabolism)</term>
<term>Ryanodine (antagonists & inhibitors)</term>
<term>Ryanodine (pharmacology)</term>
<term>Taste</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Bronchodilatateurs (pharmacologie)</term>
<term>Caféine (antagonistes et inhibiteurs)</term>
<term>Caféine (pharmacologie)</term>
<term>Chloroquine (pharmacologie)</term>
<term>Composés d'ammonium quaternaire (pharmacologie)</term>
<term>Femelle</term>
<term>Goût</term>
<term>Inhibiteurs de la phosphodiestérase ()</term>
<term>Inhibiteurs de la phosphodiestérase (pharmacologie)</term>
<term>Inhibiteurs des canaux calciques ()</term>
<term>Inhibiteurs des canaux calciques (pharmacologie)</term>
<term>Inositol 1,4,5-trisphosphate (analogues et dérivés)</term>
<term>Inositol 1,4,5-trisphosphate (métabolisme)</term>
<term>Muscles lisses ()</term>
<term>Muscles lisses (cytologie)</term>
<term>Muscles lisses (métabolisme)</term>
<term>Poumon ()</term>
<term>Poumon (cytologie)</term>
<term>Poumon (métabolisme)</term>
<term>Quinine (pharmacologie)</term>
<term>Relâchement musculaire ()</term>
<term>Ryanodine (antagonistes et inhibiteurs)</term>
<term>Ryanodine (pharmacologie)</term>
<term>Récepteurs couplés aux protéines G (agonistes)</term>
<term>Récepteurs couplés aux protéines G (métabolisme)</term>
<term>Récepteurs à l'inositol 1,4,5-triphosphate (agonistes)</term>
<term>Récepteurs à l'inositol 1,4,5-triphosphate (métabolisme)</term>
<term>Résistance aux substances ()</term>
<term>Résistance des voies aériennes ()</term>
<term>Signalisation du calcium ()</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Techniques in vitro</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Inositol 1,4,5-Trisphosphate Receptors</term>
<term>Receptors, G-Protein-Coupled</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Inositol 1,4,5-Trisphosphate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Caffeine</term>
<term>Ryanodine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Calcium Channel Blockers</term>
<term>Phosphodiesterase Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Inositol 1,4,5-Trisphosphate</term>
<term>Inositol 1,4,5-Trisphosphate Receptors</term>
<term>Receptors, G-Protein-Coupled</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Bronchodilator Agents</term>
<term>Caffeine</term>
<term>Calcium Channel Blockers</term>
<term>Chloroquine</term>
<term>Phosphodiesterase Inhibitors</term>
<term>Quaternary Ammonium Compounds</term>
<term>Quinine</term>
<term>Ryanodine</term>
</keywords>
<keywords scheme="MESH" qualifier="agonistes" xml:lang="fr"><term>Récepteurs couplés aux protéines G</term>
<term>Récepteurs à l'inositol 1,4,5-triphosphate</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Inositol 1,4,5-trisphosphate</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Caféine</term>
<term>Ryanodine</term>
</keywords>
<keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Muscles lisses</term>
<term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Lung</term>
<term>Muscle, Smooth</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Airway Resistance</term>
<term>Calcium Signaling</term>
<term>Drug Resistance</term>
<term>Lung</term>
<term>Muscle Relaxation</term>
<term>Muscle, Smooth</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lung</term>
<term>Muscle, Smooth</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Inositol 1,4,5-trisphosphate</term>
<term>Muscles lisses</term>
<term>Poumon</term>
<term>Récepteurs couplés aux protéines G</term>
<term>Récepteurs à l'inositol 1,4,5-triphosphate</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Bronchodilatateurs</term>
<term>Caféine</term>
<term>Chloroquine</term>
<term>Composés d'ammonium quaternaire</term>
<term>Inhibiteurs de la phosphodiestérase</term>
<term>Inhibiteurs des canaux calciques</term>
<term>Quinine</term>
<term>Ryanodine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Female</term>
<term>In Vitro Techniques</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Taste</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Femelle</term>
<term>Goût</term>
<term>Inhibiteurs de la phosphodiestérase</term>
<term>Inhibiteurs des canaux calciques</term>
<term>Muscles lisses</term>
<term>Poumon</term>
<term>Relâchement musculaire</term>
<term>Résistance aux substances</term>
<term>Résistance des voies aériennes</term>
<term>Signalisation du calcium</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Techniques in vitro</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">While selective, bitter tasting, TAS2R agonists can relax agonist-contracted airway smooth muscle (ASM), their mechanism of action is unclear. However, ASM contraction is regulated by Ca²⁺ signalling and Ca²⁺ sensitivity. We have therefore investigated how the TAS2R10 agonists chloroquine, quinine and denotonium regulate contractile agonist-induced Ca²⁺ signalling and sensitivity.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24117140</PMID>
<DateCompleted><Year>2014</Year>
<Month>10</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-5381</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>171</Volume>
<Issue>3</Issue>
<PubDate><Year>2014</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>British journal of pharmacology</Title>
<ISOAbbreviation>Br. J. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Bitter tasting compounds dilate airways by inhibiting airway smooth muscle calcium oscillations and calcium sensitivity.</ArticleTitle>
<Pagination><MedlinePgn>646-62</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/bph.12460</ELocationID>
<Abstract><AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">While selective, bitter tasting, TAS2R agonists can relax agonist-contracted airway smooth muscle (ASM), their mechanism of action is unclear. However, ASM contraction is regulated by Ca²⁺ signalling and Ca²⁺ sensitivity. We have therefore investigated how the TAS2R10 agonists chloroquine, quinine and denotonium regulate contractile agonist-induced Ca²⁺ signalling and sensitivity.</AbstractText>
<AbstractText Label="EXPERIMENTAL APPROACH" NlmCategory="METHODS">Airways in mouse lung slices were contracted with either methacholine (MCh) or 5HT and bronchodilation assessed using phase-contrast microscopy. Ca²⁺ signalling was measured with 2-photon fluorescence microscopy of ASM cells loaded with Oregon Green, a Ca²⁺-sensitive indicator (with or without caged-IP₃). Effects on Ca²⁺ sensitivity were assessed on lung slices treated with caffeine and ryanodine to permeabilize ASM cells to Ca²⁺ .</AbstractText>
<AbstractText Label="KEY RESULTS" NlmCategory="RESULTS">The TAS2R10 agonists dilated airways constricted by either MCh or 5HT, accompanied by inhibition of agonist-induced Ca²⁺ oscillations. However, in non-contracted airways, TAS2R10 agonists, at concentrations that maximally dilated constricted airways, did not evoke Ca²⁺ signals in ASM cells. Ca²⁺ increases mediated by the photolysis of caged-IP₃ were also attenuated by chloroquine, quinine and denotonium. In Ca²⁺-permeabilized ASM cells, the TAS2R10 agonists dilated MCh- and 5HT-constricted airways.</AbstractText>
<AbstractText Label="CONCLUSIONS AND IMPLICATIONS" NlmCategory="CONCLUSIONS">TAS2R10 agonists reversed bronchoconstriction by inhibiting agonist-induced Ca²⁺ oscillations while simultaneously reducing the Ca²⁺ sensitivity of ASM cells. Reduction of Ca²⁺ oscillations may be due to inhibition of Ca²⁺ release through IP₃ receptors. Further characterization of bronchodilatory TAS2R agonists may lead to the development of novel therapies for the treatment of bronchoconstrictive conditions.</AbstractText>
<CopyrightInformation>© 2013 The British Pharmacological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName>
<ForeName>Xiahui</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sanderson</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 HL103405</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>HL103405</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Br J Pharmacol</MedlineTA>
<NlmUniqueID>7502536</NlmUniqueID>
<ISSNLinking>0007-1188</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053496">Inositol 1,4,5-Trisphosphate Receptors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000644">Quaternary Ammonium Compounds</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592154">Tas2r107 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>15662-33-6</RegistryNumber>
<NameOfSubstance UI="D012433">Ryanodine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3G6A5W338E</RegistryNumber>
<NameOfSubstance UI="D002110">Caffeine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>85166-31-0</RegistryNumber>
<NameOfSubstance UI="D015544">Inositol 1,4,5-Trisphosphate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>A7V27PHC7A</RegistryNumber>
<NameOfSubstance UI="D011803">Quinine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000403" MajorTopicYN="N">Airway Resistance</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001993" MajorTopicYN="N">Bronchodilator Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002110" MajorTopicYN="N">Caffeine</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015544" MajorTopicYN="N">Inositol 1,4,5-Trisphosphate</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053496" MajorTopicYN="N">Inositol 1,4,5-Trisphosphate Receptors</DescriptorName>
<QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009126" MajorTopicYN="N">Muscle Relaxation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009130" MajorTopicYN="N">Muscle, Smooth</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000644" MajorTopicYN="N">Quaternary Ammonium Compounds</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011803" MajorTopicYN="N">Quinine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName>
<QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012433" MajorTopicYN="N">Ryanodine</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013649" MajorTopicYN="N">Taste</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2-photon microscopy</Keyword>
<Keyword MajorTopicYN="N">TAS2R</Keyword>
<Keyword MajorTopicYN="N">asthma</Keyword>
<Keyword MajorTopicYN="N">mouse lung slice</Keyword>
<Keyword MajorTopicYN="N">β2-adrenergic receptor agonists</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year>
<Month>02</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2013</Year>
<Month>09</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2013</Year>
<Month>09</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>10</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>10</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>10</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24117140</ArticleId>
<ArticleId IdType="doi">10.1111/bph.12460</ArticleId>
<ArticleId IdType="pmc">PMC3969078</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Biol Chem. 2010 Jan 15;285(3):2203-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19920135</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1994 Mar 25;269(12):8701-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8132598</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Cell Mol Biol. 2010 Mar;42(3):373-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19502388</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Physiol. 2010 Mar;135(3):247-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20176853</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Cell Mol Biol. 2010 Aug;43(2):179-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19767449</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2010 Nov;16(11):1299-304</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20972434</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Cell Mol Biol. 2011 Nov;45(5):1069-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21642585</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2012 Jan;40(Database issue):D413-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21940398</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Physiol (Oxf). 2012 Feb;204(2):158-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21481196</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2012 May;18(5):648-50; author reply 650-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22561814</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Heart Circ Physiol. 2012 Jun 1;302(11):H2190-210</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22447942</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Lung Cell Mol Physiol. 2012 Dec 1;303(11):L956-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22962016</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2012 Dec 7;287(50):41706-19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23095746</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Physiol. 2013 Feb;141(2):165-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23359281</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pulm Pharmacol Ther. 2013 Feb;26(1):121-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22750270</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Biol. 2013;11(3):e1001501</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23472053</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Pharmacol. 2013 Dec;170(8):1449-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24528237</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2000 Mar 9;404(6774):197-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10724174</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2000 Mar 17;100(6):703-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10761935</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods Mol Biol. 2001;154:407-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11218662</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2003 Feb 7;112(3):293-301</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12581520</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Lung Cell Mol Physiol. 2004 May;286(5):L909-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14617522</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Pharmacol Sci. 1988 Jun;9(6):195-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2854671</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Cell Biochem. 1997 Feb;64(2):225-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9027583</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol. 1997 Apr;272(4 Pt 1):L659-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9142939</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Appl Physiol (1985). 1997 Jun;82(6):1836-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9173948</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Cell Biol. 1998 Nov;77(3):253-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9860142</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Physiol. 2005 Jun;125(6):535-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15928401</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Physiol. 2005 Jun;125(6):555-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15928402</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Respir Res. 2006;7:34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16504084</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Lung Cell Mol Physiol. 2006 Aug;291(2):L208-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16461427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem J. 2007 May 1;403(3):537-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17253962</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Cell Mol Biol. 2007 May;36(5):600-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17170384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Am Thorac Soc. 2008 Jan 1;5(1):23-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18094081</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Cell Mol Biol. 2008 May;38(5):524-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18063837</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2008 Aug;32(2):275-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18353852</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L947-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19346434</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L347-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19465516</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2009 Aug 28;325(5944):1131-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19628819</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2951-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1849282</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Senses. 2010 Feb;35(2):157-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20022913</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Massachusetts</li>
</region>
</list>
<tree><noCountry><name sortKey="Sanderson, Michael J" sort="Sanderson, Michael J" uniqKey="Sanderson M" first="Michael J" last="Sanderson">Michael J. Sanderson</name>
</noCountry>
<country name="États-Unis"><region name="Massachusetts"><name sortKey="Tan, Xiahui" sort="Tan, Xiahui" uniqKey="Tan X" first="Xiahui" last="Tan">Xiahui Tan</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000303 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000303 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:24117140 |texte= Bitter tasting compounds dilate airways by inhibiting airway smooth muscle calcium oscillations and calcium sensitivity. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:24117140" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
This area was generated with Dilib version V0.6.33. |